Clinical trial for Angina
Official title Imaging Coronary Microvascular Dysfunction (CMD) Study
ClinicalTrials.gov ID: NCT05634031
What this study is testing
- What it's testing
- The study aims to create and check a non‑invasive method using cardiac PET imaging to identify microvascular problems in people with angina but no obstructive coronary disease, and to see if PET‑guided care improves symptoms and quality of life.
- Who it's for
- Adults who have angina and have been found to have non‑obstructive coronary artery disease (INOCA).
- What's involved
- Participants will have a cardiac PET scan (and possibly a CT scan) and will attend scheduled clinic visits for follow‑up assessments of symptoms and quality of life; a small group will also join a sub‑study with additional procedures.
- Time commitment
- The study runs for up to two years, with imaging appointments and follow‑up visits scheduled during that time.
- Time commitment: about 2 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients with symptoms of exertional angina and/or dyspnea (confirmed on Seattle Angina Questionnaire and Rose Dyspnea Questionnaire)
- Evidence of non-obstructive CAD on CCTA or coronary angiography (no stenosis \>50% and/or FFR if performed \>0.80)
You likely can't join if
- Patients with reduced LVEF (\<50%) or diagnosis of cardiomyopathy
- Patients with co-existent moderate or severe valve disease
- Patients with eGFR \<30 ml/min/m2
- History of prior coronary revascularization
- Non-coronary indication for CCTA or coronary angiogram determining eligibility
- Contraindications to regadenoson (severe asthma/chronic obstructive pulmonary disease, brady-arrhythmias, or systolic blood pressure \<90 mm Hg)
See the full eligibility criteria
- Patients with symptoms of exertional angina and/or dyspnea (confirmed on Seattle Angina Questionnaire and Rose Dyspnea Questionnaire)
- Evidence of non-obstructive CAD on CCTA or coronary angiography (no stenosis \>50% and/or FFR if performed \>0.80)
- Patients with reduced LVEF (\<50%) or diagnosis of cardiomyopathy
- Patients with co-existent moderate or severe valve disease
- Patients with eGFR \<30 ml/min/m2
- History of prior coronary revascularization
- Non-coronary indication for CCTA or coronary angiogram determining eligibility
- Contraindications to regadenoson (severe asthma/chronic obstructive pulmonary disease, brady-arrhythmias, or systolic blood pressure \<90 mm Hg)
- Inability to provide informed consent
- Pregnancy
The study team makes the final eligibility decision.
Where it is enrolling
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 2 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at New York, New York, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.